• norsk
    • English
  • English 
    • norsk
    • English
  • Login
View Item 
  •   Home
  • Norges Handelshøyskole
  • Centre for Applied Research at NHH (SNF)
  • Reports (SNF)
  • View Item
  •   Home
  • Norges Handelshøyskole
  • Centre for Applied Research at NHH (SNF)
  • Reports (SNF)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Prophylaxis with fondaparinux versus enoxaparin against venous thromboembolism after major orthopaedic surgery

Bjorvatn, Afsane
Research report
Thumbnail
View/Open
R01_05.pdf (235.6Kb)
URI
http://hdl.handle.net/11250/165139
Date
2005-03
Metadata
Show full item record
Collections
  • Reports (SNF) [542]
Abstract
Fondaparinux (Arixtra®) is a new antithrombotic agent, which is indicated for venous thromboembolism (VTE) prophylaxis after major orthopaedic surgery. This report presents cost-effectiveness analysis of fondaparinux compared with enoxaparin, the most common prophylaxis of VTE. The cost-effectiveness of short-term duration (one week) prophylaxis as well as prolonged prophylaxis (four weeks) with fondaparinux versus enoxaparin are examined. The models used in the analyses are developed to simulate the impact of prophylaxis with fondaparinux compared with enoxaparin after major orthopaedic surgery. The analyses are based on Norwegian data, which include about 55.000 patients who underwent major orthopaedic surgery in the period from 1999 to 2001. All cost estimates in the models are based on Norwegian unit costs.
Publisher
SNF
Series
Report
2005:1

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit
 

 

Browse

ArchiveCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsDocument TypesJournalsThis CollectionBy Issue DateAuthorsTitlesSubjectsDocument TypesJournals

My Account

Login

Statistics

View Usage Statistics

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit